Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study

Arthritis and Rheumatism
D O CleggW G Henderson

Abstract

To determine whether sulfasalazine (SSZ) at a dosage of 2,000 mg/day is effective for the treatment of active ankylosing spondylitis (AS) that is not controlled with nonsteroidal antiinflammatory drug therapy. Two hundred sixty-four patients with AS were recruited from 15 clinics, randomized (double-blind) to SSZ or placebo treatment, and followed up for 36 weeks. Treatment response was based on morning stiffness, back pain, and physician and patient global assessments. While longitudinal analysis revealed a trend favoring SSZ in the middle of treatment, no difference was seen at the end of treatment. Response rates were 38.2% for SSZ and 36.1% for placebo (P = 0.73). The Westergren erythrocyte sedimentation rate declined more with SSZ treatment than with placebo (P < 0.0001). AS patients with associated peripheral arthritis showed improvement that favored SSZ (P = 0.02). Adverse reactions were fewer than expected and were mainly due to nonspecific gastrointestinal complaints. SSZ at a dosage of 2,000 mg/day does not seem to be more effective than placebo in the treatment of AS patients with chronic, longstanding disease. SSZ is well tolerated and may be more effective than placebo in the treatment of AS patients with periphera...Continue Reading

References

Feb 1, 1990·British Journal of Rheumatology·S M Fraser, R D Sturrock
May 1, 1986·Annals of the Rheumatic Diseases·N Feltelius, R Hällgren
Mar 1, 1987·Annals of the Rheumatic Diseases·M ManderW C Dick
Jan 1, 1972·Annals of the Rheumatic Diseases·J M Moll, V Wright
Dec 1, 1984·Annals of Internal Medicine·B AmorF Delrieu

❮ Previous
Next ❯

Citations

Nov 30, 2000·Arthritis Care and Research : the Official Journal of the Arthritis Health Professions Association·A Falkenbach
Jul 13, 2002·Arthritis and Rheumatism·Michael M Ward, Susana Kuzis
Jun 27, 2006·Rheumatology International·Melissa PadovanFrancesco Trotta
Jun 30, 2009·Rheumatology International·L Goh, A Samanta
Mar 16, 2007·Clinical Rheumatology·Huei-Huang HoLieh-Bang Liou
May 27, 2008·Wiener medizinische Wochenschrift·Hans-Eckhard Langer
Apr 11, 2012·Nature Reviews. Rheumatology·Joachim Sieper
May 3, 2002·The New England Journal of Medicine·Jennifer D GormanJohn C Davis
Aug 24, 1999·Inflammatory Bowel Diseases·A L Buchman
Apr 20, 2005·Current Opinion in Rheumatology·Allen Anandarajah, Christopher T Ritchlin
Jun 16, 2005·Current Opinion in Rheumatology·Jane Zochling, Jürgen Braun
Apr 7, 2007·Current Opinion in Rheumatology·Augustine M ManadanJoel A Block
Sep 4, 2004·Annals of the Rheumatic Diseases·A CalinS Fatenejad
May 20, 2005·Annals of the Rheumatic Diseases·J C van DenderenI E van der Horst-Bruinsma
Aug 19, 2003·Annals of the Rheumatic Diseases·D D Gladman
Feb 2, 2008·Digestion·Pascal JuilleratPierre Michetti
Sep 24, 2013·BMC Musculoskeletal Disorders·Sanae Ali Ou AllaNajia Hajjaj-Hassouni
Jul 2, 2004·Arthritis Research & Therapy·Paul M Peloso, Jürgen Braun
Jan 6, 2011·Arthritis Research & Therapy·Andrew Barr, Andrew Keat
Nov 24, 2007·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·M RudwaleitJ Sieper
Nov 29, 2013·Annals of the Rheumatic Diseases·Tone Wikene NystadBjørg-Tilde Svanes Fevang
May 15, 2003·Current Treatment Options in Gastroenterology·Adrian A. Van Bodegraven, A. Salvador Peña
Jul 18, 2001·Springer Seminars in Immunopathology·A M van TubergenS van der Linden
Jul 27, 2001·Current Treatment Options in Gastroenterology·Ad A. van BodegravenStephan G. M. Meuwissen
Dec 10, 2014·Best Practice & Research. Clinical Rheumatology·Enrique Roberto SorianoLiron Caplan
Oct 9, 2012·Journal of Crohn's & Colitis·Gert Van AsscheUNKNOWN European Crohn's and Colitis Organisation
Jul 28, 2005·Current Rheumatology Reports·Soumya M Reddy, Clifton O Bingham III
Aug 21, 2009·Current Rheumatology Reports·Peter Nash
Dec 3, 2010·Journal of Crohn's & Colitis·Gert Van AsscheUNKNOWN European Crohn's and Colitis Organisation (ECCO)
Jan 15, 2014·Expert Review of Clinical Immunology·Francesca IngegnoliEnnio Lubrano
Jun 27, 2002·Expert Opinion on Investigational Drugs·Walter P Maksymowych
Dec 1, 2001·Scandinavian Journal of Rheumatology·L AltanM Yurtkuran
May 1, 2012·The American Journal of the Medical Sciences·Enrique R SorianoJeffrey R Lisse
May 1, 2012·The American Journal of the Medical Sciences·Shirley M L TseRobert A Colbert
Sep 26, 2013·Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi·Jen-Jia YangShan-Chwen Chang
Dec 8, 2009·Rheumatic Diseases Clinics of North America·Theodore PincusTuulikki Sokka

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.